

Jan Beyer-Westendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5738109/publications.pdf>

Version: 2024-02-01

191
papers

11,017
citations

50273

46
h-index

31843

101
g-index

199
all docs

199
docs citations

199
times ranked

9301
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	27.0	1,221
2	Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. <i>Circulation</i> , 2014, 129, 479-486.	1.6	794
3	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	27.0	692
4	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
5	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	27.0	577
6	American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. <i>Blood Advances</i> , 2018, 2, 3198-3225.	5.2	492
7	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , 2019, 20, e566-e581.	10.7	458
8	Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. <i>Blood</i> , 2014, 124, 955-962.	1.4	363
9	Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. <i>European Heart Journal</i> , 2014, 35, 1888-1896.	2.2	320
10	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	2.8	258
11	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology</i> , 2014, 1, e37-e46.	4.6	244
12	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	2.8	244
13	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	5.1	180
14	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
15	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , 2016, 127, 1417-1425.	1.4	156
16	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	3.4	154
17	Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1150-1157.	1.7	132
18	Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry. <i>Europace</i> , 2015, 17, 530-538.	1.7	127

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1247-1257.	3.4	127
20	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1874-1882.	3.8	122
21	Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 939-949.	3.4	114
22	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , 2017, 4, e105-e113.	4.6	112
23	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.2	106
24	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1713-1720.	1.6	90
25	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 129-143.	2.1	87
26	Edoxaban for treatment of venous thromboembolism in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1268-1276.	3.4	79
27	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	3.4	79
28	Bleeding complications during anticoagulant treatment in patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S49-S55.	1.7	73
29	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	5.2	71
30	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2014, 160, 451.	3.9	62
31	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	3.8	60
32	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. <i>Thrombosis and Haemostasis</i> , 2016, 116, 739-746.	3.4	58
33	Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) – findings from the GerHIT multi-centre registry study. <i>Thrombosis Research</i> , 2014, 134, 29-35.	1.7	57
34	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
35	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014, 12, 25.	2.1	55
36	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	4.6	55

#	ARTICLE	IF	CITATIONS
37	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 733-738.	3.4	55
38	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	2.1	54
39	Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. <i>Lancet Haematology</i> , 2016, 3, e480-e488.	4.6	53
40	Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2636-2648.	2.8	53
41	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
42	Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 908-917.	2.4	51
43	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	4.6	51
44	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.4	50
45	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 645-650.	3.4	48
46	Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2013, 109, 154-163.	3.4	47
47	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	1.7	47
48	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017, 227, 261-266.	1.7	47
49	Successful treatment of acute portal vein thrombosis with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 626-627.	3.4	44
50	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	3.3	44
51	Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 533-535.	2.1	42
52	Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 231-246.	3.4	40
53	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 099-105.	2.7	39
54	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016, 116, S13-S23.	3.4	39

#	ARTICLE	IF	CITATIONS
55	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	3.4	38
56	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e884-e891.	4.6	38
57	Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1234-1236.	3.4	32
58	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. <i>Journal of Gastroenterology</i> , 2017, 52, 1211-1220.	5.1	31
59	Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 169-178.	2.1	31
60	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine – A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	3.4	30
61	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2107-2114.	4.4	29
62	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , 2020, 36, 1081-1088.	1.9	29
63	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 1051-1058.	2.0	25
64	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	2.0	25
65	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. <i>Chest</i> , 2016, 150, 1059-1068.	0.8	24
66	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	3.7	24
67	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	1.7	24
68	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1325-1332.	1.8	23
69	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	3.4	23
70	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	5.8	23
71	What have we learned from real-world NOAC studies in venous thromboembolism treatment?. <i>Thrombosis Research</i> , 2018, 163, 83-91.	1.7	22
72	Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 223-230.	2.5	22

#	ARTICLE	IF	CITATIONS
73	Safety of venous ultrasound in suspected DVT – still a matter of concern?. <i>Thrombosis and Haemostasis</i> , 2009, 102, 5-6.	3.4	21
74	Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1076-1084.	3.4	21
75	Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. <i>International Journal of Cardiology</i> , 2018, 257, 276-282.	1.7	21
76	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 933-938.e1.	1.5	21
77	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients. <i>Thrombosis Journal</i> , 2019, 17, 24.	2.1	21
78	Definition of major bleeding: Prognostic classification. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2852-2860.	3.8	21
79	Direct Oral Anticoagulants and Women. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 789-797.	2.7	20
80	COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.	2.1	20
81	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	2.3	20
82	Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. <i>Journal of Gastroenterology</i> , 2018, 53, 236-246.	5.1	19
83	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 349-358.	2.1	19
84	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	5.2	19
85	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 575-582.	1.7	18
86	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 235-242.	2.2	17
87	Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 197-204.	2.1	17
88	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. <i>Lancet Haematology</i> , 2018, 5, e441-e449.	4.6	17
89	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. <i>European Journal of Internal Medicine</i> , 2020, 75, 35-43.	2.2	17
90	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	6.7	17

#	ARTICLE	IF	CITATIONS
91	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. <i>Blood Advances</i> , 2022, 6, 4516-4523.	5.2	16
92	A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. <i>Thrombosis Research</i> , 2016, 148, 59-62.	1.7	15
93	Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 293-300.	2.1	15
94	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. <i>Thrombosis Journal</i> , 2019, 17, 6.	2.1	15
95	Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 26-36.	2.1	14
96	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	1.7	14
97	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. <i>Thrombosis Research</i> , 2018, 168, 31-36.	1.7	14
98	Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 31-38.	0.9	14
99	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	3.4	14
100	Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. <i>Blood</i> , 2019, 134, 2159-2159.	1.4	14
101	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 166-177.	2.7	13
102	Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number) <i>Tj ETQq0 Q,0 rgBT /Qverlock 10</i>	1.8	13
103	Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery â€“ findings from the ORTHOâ€“EP registry. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 947-958.	2.4	12
104	Clinical history of cancerâ€“associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	3.8	12
105	Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). <i>Thrombosis and Haemostasis</i> , 2021, 121, 206-215.	3.4	12
106	Sex hormones and venous thromboembolism â€“ from contraception to hormone replacement therapy. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 441-450.	1.4	12
107	Severe Hemorrhage Associated With Oral Anticoagulants. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 312-319.	0.9	12
108	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 491-497.	4.9	11

#	ARTICLE	IF	CITATIONS
109	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	1.7	11
110	DOACS in women: pros and cons. <i>Thrombosis Research</i> , 2019, 181, S19-S22.	1.7	11
111	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	4.4	11
112	Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report. <i>TH Open</i> , 2021, 05, e315-e318.	1.4	11
113	Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 715-716.	2.4	10
114	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. <i>European Heart Journal Supplements</i> , 2015, 17, D32-D41.	0.1	10
115	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 339-345.	2.1	10
116	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.	1.7	10
117	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). <i>Thrombosis Journal</i> , 2019, 17, 7.	2.1	9
118	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	3.4	9
119	Reproductive issues in women on direct oral anticoagulants. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12512.	2.3	9
120	Increase of Gastrointestinal Bleeding With New Oral Anticoagulants: Problems of a Meta-analysis. <i>Gastroenterology</i> , 2013, 145, 1162-1163.	1.3	8
121	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1112-1115.	3.8	8
122	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 552-559.	3.4	8
123	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	1.7	7
124	Betrixaban for prevention of venous thromboembolism in acute medically ill patients. <i>European Heart Journal Supplements</i> , 2018, 20, E16-E22.	0.1	7
125	5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. <i>Thrombosis Research</i> , 2021, 202, 24-30.	1.7	7
126	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	1.4	7

#	ARTICLE	IF	CITATIONS
127	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	3.8	7
128	Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 777-787.	2.1	7
129	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	2.0	6
130	Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 553-560.e1.	1.6	6
131	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 499-506.	3.8	6
132	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. <i>European Journal of Haematology</i> , 2019, 102, 143-149.	2.2	6
133	Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Research</i> , 2020, 190, 91-98.	1.7	6
134	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	2.3	6
135	Point of care coagulation management in anesthesiology and critical care. <i>Minerva Anestesiologica</i> , 2022, 88, .	1.0	6
136	Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes. <i>Thrombosis Research</i> , 2015, 136, 261-266.	1.7	5
137	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2019, 282, 47-52.	1.7	5
138	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021, 05, e353-e362.	1.4	5
139	Predictors of deep venous thrombosis in patients admitted to rehabilitation clinics after major orthopaedic surgery. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 40-49.	1.4	5
140	Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2013, 122, 2380-2380.	1.4	5
141	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. <i>European Heart Journal Supplements</i> , 2015, 17, D42-D52.	0.1	4
142	Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. <i>Orthopedic Research and Reviews</i> , 2017, Volume 9, 1-11.	1.1	4
143	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , 2018, 154, 1371-1378.	0.8	4
144	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	1.7	4

#	ARTICLE	IF	CITATIONS
145	579â€fThe Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. American Journal of Gastroenterology, 2019, 114, S332-S333.	0.4	4
146	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. American Journal of Medicine, 2019, 132, 498-504.	1.5	4
147	Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism. Scientific Reports, 2021, 11, 9569.	3.3	4
148	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry. Kardiologia Polska, 2021, 79, 1265-1267.	0.6	4
149	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. American Journal of Medicine, 2021, , .	1.5	4
150	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095491.	1.7	3
151	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	2.3	3
152	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	1.4	3
153	Centrally Adjudicated Cause of Death during Noac Treatment â€ Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2014, 124, 2876-2876.	1.4	3
154	Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2015, 126, 892-892.	1.4	3
155	Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2016, 128, 2618-2618.	1.4	3
156	Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial. Blood, 2016, 128, 85-85.	1.4	3
157	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study. Blood, 2018, 132, 1241-1241.	1.4	3
158	Cancerâ€Associated ThrOmboSis â€ Patientâ€Reported OutcoMes With RivarOxaban (COSIMO) â€ Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12604.	2.3	3
159	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurological Research and Practice, 2022, 4, 16.	2.0	3
160	Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. Thrombosis Research, 2022, 215, 37-40.	1.7	3
161	Small clots with large impact. Blood, 2015, 126, 926-927.	1.4	2
162	Deep Vein Thrombosis â€ Current Management Strategies. Clinical Medicine Insights Therapeutics, 2016, 8, CMT.S18890.	0.4	2

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations. <i>Hamostaseologie</i> , 2018, 38, 87-97.	1.9	2
164	Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119). <i>Thrombosis Research</i> , 2020, 191, 50-55.	1.7	2
165	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: A Prospective Management Study. <i>Blood</i> , 2012, 120, 391-391.	1.4	2
166	Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial. <i>Blood</i> , 2019, 134, 2161-2161.	1.4	2
167	Cancer in males and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2010, 125, S155-S159.	1.7	1
168	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019, 104, e474-e477.	3.5	1
169	Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease. <i>Angiology</i> , 2020, 71, 773-790.	1.8	1
170	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. <i>Hamostaseologie</i> , 2021, 41, 035-041.	1.9	1
171	Checkpoint inhibitors and thrombosis: what's up?. <i>Blood</i> , 2021, 137, 1569-1570.	1.4	1
172	Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry. <i>TH Open</i> , 2021, 05, e143-e151.	1.4	1
173	Every 6 seconds in Europe. <i>Thrombosis Research</i> , 2021, , .	1.7	1
174	Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Update</i> , 2021, 5, 100070.	0.9	1
175	Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry. <i>Blood</i> , 2014, 124, 4264-4264.	1.4	1
176	Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2015, 126, 1131-1131.	1.4	1
177	Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1. <i>European Heart Journal Supplements</i> , 2015, 17, D21-D28.	0.1	0
178	Letter to the Editor – Gender related aspects of bleeding with rivaroxaban in venous thromboembolism – Potential for pitfalls. <i>Thrombosis Research</i> , 2016, 148, 152-153.	1.7	0
179	Independent data about the safety and efficacy of rivaroxaban for prevention of stroke/embolism are needed: Author reply. <i>Europace</i> , 2016, 18, 156.2-158.	1.7	0
180	Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e254-e255.	4.6	0

#	ARTICLE	IF	CITATIONS
181	Response to the Letter by Lucijanic et al., regarding our manuscript "Management and outcome of gastro-intestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs" Journal of Gastroenterology, 2017, 52, 1077-1078.	5.1	0
182	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. Journal of Thrombosis and Haemostasis, 2019, 17, 1398-1399.	3.8	0
183	Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery. Blood, 2011, 118, 210-210.	1.4	0
184	Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Acquired Pulmonary Embolism. Blood, 2012, 120, 3416-3416.	1.4	0
185	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. Blood, 2014, 124, 592-592.	1.4	0
186	Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy. Blood, 2016, 128, 141-141.	1.4	0
187	NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years " Results of the Prospective Dresden NOAC Registry (NCT01588119). Blood, 2018, 132, 422-422.	1.4	0
188	In Reply. Deutsches Ärzteblatt International, 2019, 116, 420-421.	0.9	0
189	Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2019, 134, 3667-3667.	1.4	0
190	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
191	Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY. Thrombosis Research, 2021, 208, 181-189.	1.7	0